Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06275685 · ClinicalTrials.gov registry record · NA

Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking

A NA study of Epilepsy; Seizure, sponsored by Empatica.

Recruiting
Registry status
NA
Development phase
3,000
Enrollment target
1
Study location

NCT06275685: Recruiting NA study of Epilepsy; Seizure, sponsored by Empatica.

NCT06275685 is a NA study of Epilepsy; Seizure that is actively recruiting participants, run by Empatica. The registered enrollment target is 3,000 participants, above the 36-participant average among 4 other Epilepsy; Seizure trials with a reported enrollment target (8233% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06275685, a NA study of Epilepsy; Seizure, is actively recruiting participants, sponsored by Empatica.

RECRUITING
Registry status
NA
Development phase
3,000 participants
Enrollment target
1
Study location

Study Summary

The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy. The main questions it aims to answer are: * can we develop a future seizure probabilities tool that is more accurate than chance based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables. * does this tool improve the lives of people with epilepsy? Researchers will compare a group that does not have access to the forecast tool to a group that does and see if it is accurate and if people with it report that it improved their quality of life.

Primary Outcome

Percentage of patients with (1) sensitivity of high-likelihood warnings greater than 60% and (2) superior to a rate-matched forecast (or superior baselining method) at the end of Phase 2.

Conditions Studied

Interventions

  • DEVICE SeizureWise algorithm
  • DEVICE Multi-day Visualizations

Study Locations (1)

Massachusetts

  • Empatica - Boston

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2024-04-11
Est. Completion 2026-06
Phase NA
Empatica

3 total trials

What NCT06275685 shows while recruiting

NCT06275685 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 36-participant average among 4 other Epilepsy; Seizure trials with a reported enrollment target (8233% higher).

The record links to 1 condition, with Epilepsy; Seizure appearing as the primary indexed condition, and to 2 interventions - of which SeizureWise algorithm is the first listed.

NCT06275685 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06275685 about?

NCT06275685 is a clinical study titled "Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking". The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy. The main questions it aims to answer are: * can we develop a future seizure probabilities tool that is more accurate than chance based on the pattern and frequency of previous gen...

What is the current status of trial NCT06275685?

This trial is currently recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2024-04-11. Estimated completion is 2026-06.

What conditions does trial NCT06275685 study?

This clinical trial studies the following conditions: Epilepsy; Seizure.

What interventions are being tested in trial NCT06275685?

The interventions under investigation include: SeizureWise algorithm (DEVICE), Multi-day Visualizations (DEVICE).

Who is sponsoring clinical trial NCT06275685?

This trial is sponsored by Empatica, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06275685 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy; Seizure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06275685, the US trial registry maintained by the National Library of Medicine. NCT06275685 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.